The Defense Health Agency awarded Yale University a $1,671,258 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to develop engineered neuronal-specific therapeutic mRNA to treat Rett syndrome. The grant has a performance period from December 15, 2024 to December 14, 2026. Through this award, Yale University will conduct research to advance novel gene therapy approaches for this neurological disorder affecting the nervous system. The funding supports Yale's efforts to engineer and evaluate mRNA therapeutics that target the specific neuronal cells impacted by Rett syndrome.
Generated 3/4/25, 4:24 AM